LONDON (AP) — AstraZeneca on Tuesday outlined plans to make sales jump over the next decade, an effort to persuade shareholders the drug maker can do well as an independent company, rather than get bought out by rival Pfizer.

In a statement, AstraZeneca said investors would share the benefits of a “strong and consistent revenue growth” that would see annual sales rise to more than $45 billion by 2023 from $25.7 billion last year.

Recommended Stories

The arrival of divided government

Abdul el Sayed defeats Mike Rogers in Michigan race, poised to become first Muslim senator

Jocelyn Benson wins Michigan gubernatorial race, continuing historic Democratic streak